RT Journal Article
SR Electronic
T1 Aldosterone receptor antagonists for heart failure: Current status, future indications
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 257
OP 268
VO 73
IS 3
A1 Pitt, Bertram
A1 Rajagopalan, Sanjay
YR 2006
UL http://www.ccjm.org/content/73/3/257.abstract
AB Many patients with heart failure should receive an aldosterone receptor antagonist, ie, either spironolactone (Aldactone) or the newer agent eplerenone (Inspra)—in addition to an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) or both, and a beta-blocker. We review the evidence and indications.